Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield
Connecticut
06877
United States
Tel: 203-798-9988
Website: http://us.boehringer-ingelheim.com/
191 articles with Boehringer Ingelheim Pharmaceuticals, Inc.
-
Boehringer Ingelheim announces appointments to Board of Managing Directors
12/20/2022
Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors.
-
Eli Lilly and Boehringer Ingelheim declared another victory Wednesday for Jardiance – this one for children and adolescents with Type 2 Diabetes.
-
Therapeutics to halt the progression of chronic kidney disease are in Phase III trials, and others will enter that stage soon. NDAs could follow as early as 2024 with regulatory determinations in 2025.
-
Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD
11/17/2022
Boehringer Ingelheim Pharmaceuticals Inc. welcomes the updated 2023 Global Initiative for Chronic Obstructive Lung Disease Report recommending long‐acting muscarinic antagonist plus long‐acting beta‐agonist as the optimal first-line treatment option for most patients with COPD, regardless of exacerbation risk.
-
Surrozen announced it paused its Phase I study in Crohn’s disease and ulcerative colitis as several healthy participants showed increased levels of liver enzymes.
-
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
10/26/2022
Boehringer Ingelheim today announced that the first U.S. patient has enrolled in FIBRONEER™-IPF, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B (PDE4B) inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).
-
Surrozen announced Thursday it has partnered with Boehringer Ingelheim to research and develop a therapeutic for the treatment of retinal diseases.
-
More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development
9/13/2022
Keynote speakers AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK headline one of the industry's largest events for driving collaboration and innovation.
-
Boehringer announced that the FDA approved Spevigo for generalized pustular psoriasis flares in adults, the first drug approved for this indication.
-
Recent advances in precision medicine and genomics have launched an explosion in immunotherapies that are resulting in real cures and earlier diagnoses - and more healthy years for individuals.
-
Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.
-
Many healthcare, pharmaceutical and biotech companies continue to place their bets on China, bringing fresh rounds of investments to and forging new partnerships with local firms.
-
BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
6/2/2022
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.
-
Illumina and Deerfield Management have entered into a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies.
-
Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
-
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
-
The initial program will focus on one degrader combined with multiple proprietary E3 ligase platforms and use VantAI’s geometric deep learning platform.
-
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
-
Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.